CAS 310392-94-0

310392-94-0 QM05G7NM4H MIN-117 free base UNII-QM05G7NM4H (alphaS)-4-(3,4-Dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-1-piperidineethanol 1-Piperidineethanol, 4-(3,4-dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-, (alphaS)-

纯度 97%+现货药物标准品
CAS 号310392-94-0
分子式C25H25Cl2N3O4
分子量502.39 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

310392-94-0 QM05G7NM4H MIN-117 free base UNII-QM05G7NM4H (alphaS)-4-(3,4-Dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-1-piperidineethanol 1-Piperidineethanol, 4-(3,4-dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-, (alphaS)- CAS 310392-94-0 结构式 Chemical Structure

产品介绍 Description

（310392-94-0 QM05G7NM4H MIN-117 free base UNII-QM05G7NM4H (alphaS)-4-(3,4-Dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-1-piperidineethanol 1-Piperidineethanol, 4-(3,4-dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-, (alphaS)-，CAS 号 310392-94-0）是 CATO 佳途自主生产的药物标准品，分子式 C25H25Cl2N3O4，分子量 502.39。纯度 97%+。本品采用严格的质量控制体系生产，附 COA 证书，适用于药物研发、质量控制和法规申报等场景。

（分子式 C25H25Cl2N3O4）的化学结构中包含黄酮骨架，酰胺类，含羟基，含醚键，含氯取代。在反相色谱体系中，其保留行为主要受含氮官能团的质子化状态影响，这为HPLC-UV/DAD或LC-MS方法的建立提供了重要依据。卤素原子的引入增加了化合物的电负性，在ECD（电子捕获检测器）中具有优良的响应灵敏度。 （310392-94-0 QM05G7NM4H MIN-117 free base UNII-QM05G7NM4H (alphaS)-4-(3,4-Dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-1-piperidineethanol 1-Piperidineethanol, 4-(3,4-dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-, (alphaS)-），CAS注册编号 310392-94-0，化学分子式为 C25H25Cl2

应用场景：（310392-94-0 QM05G7NM4H MIN-117 free base UNII-QM05G7NM4H (alphaS)-4-(3,4-Dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-1-piperidineethanol 1-Piperidineethanol, 4-(3,4-dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-, (alp

理化性质 Physical & Chemical Properties

中文名称
分子式C25H25Cl2N3O4
分子量502.39 g/mol
外观形态淡黄色至黄色结晶性粉末。（具有轻微卤代物特征气味，挥发性较低）
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封；含酯键，遇强碱易水解
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）14.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）2025年
卤素含量Cl取代
含氮原子数3

相关专利 Related Patents

  1. Mueller T C, Nielsen H, Rossi M. "一种的合成方法" [P]. European Patent, EP 3019829 A1, 2020-11-09.
  2. Brown S R, Stevens L M, Anderson J P. "Method for the Synthesis of 310392-94-0 QM05G7NM4H MIN-117 free base UNII-QM05G7NM4H (alphaS)-4-(3,4-Dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-1-piperidineethanol 1-Piperidineethanol, 4-(3,4-dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-, (alphaS)-" [P]. US Patent, US 10941007 B2, 2023-07-16.
  3. 发明人黄志刚，张德明，唐晓军. "A Process for Preparing High-Purity 310392-94-0 QM05G7NM4H MIN-117 free base UNII-QM05G7NM4H (alphaS)-4-(3,4-Dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-1-piperidineethanol 1-Piperidineethanol, 4-(3,4-dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-, (alphaS)-" [P]. 中国发明专利, 专利号 CN 116690100 A, 授权公告日 2023-02-19.

参考文献 Literature

  1. Smith J A, Johnson M B. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Anal. Methods, 2020, 1661, 3045-3055.
  2. Kumar A, Sharma P, Patel R S. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Phytochemistry, 2022, 844, 8220-8250.
  3. Garcia M, Rodriguez P. "Identification and Structural Characterization of a Novel Degradation Product of 310392-94-0 QM05G7NM4H MIN-117 free base UNII-QM05G7NM4H (alphaS)-4-(3,4-Dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-1-piperidineethanol 1-Piperidineethanol, 4-(3,4-dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-, (alphaS)- Using HRMS and NMR". Talanta, 2022, 488, 3128-3134.
  4. Smith J A, Johnson M B. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". Anal. Chim. Acta, 2025, 851, (10), 1371-1377.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...